Ocugen Inc Market Cap ($252.27 Million)
Market Cap & Net Worth: Ocugen Inc (OCGN)
Ocugen Inc market cap. Ocugen Inc (NASDAQ:OCGN) has a market capitalization of $252.27 Million ($252.27 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #15368 globally and #3660 in its home market, demonstrating a 5.19% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Ocugen Inc's stock price $0.75 by its total outstanding shares 338521856 (338.52 Million). Also see OCGN cash flow conversion for how efficiently the company converts equity into cash flow.
Ocugen Inc Market Cap History (2015–2026)
Ocugen Inc market cap history from 2015 to 2026. Data shows change from $71.09 Billion to $252.27 Million (-41.31% CAGR). Check OCGN stock price and chart for real-time trading data and today's change.
Index Memberships
Ocugen Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.01% | #406 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #1498 of 3165 |
Weight: Ocugen Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Ocugen Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Ocugen Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Ocugen Inc annual equity growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
103.56x
Ocugen Inc's market cap is 103.56 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $176.03 Million | $42.62K | -$20.24 Million | 4130.25x | N/A |
| 2020 | $619.49 Million | $43.00K | -$21.82 Million | 14406.86x | N/A |
| 2021 | $1.54 Billion | $22.92K | -$58.37 Million | 67202.20x | N/A |
| 2022 | $440.08 Million | $2.49 Million | -$77.83 Million | 176.88x | N/A |
| 2023 | $194.65 Million | $6.04 Million | -$63.08 Million | 32.25x | N/A |
| 2024 | $272.51 Million | $4.05 Million | -$54.05 Million | 67.20x | N/A |
| 2025 | $457.00 Million | $4.41 Million | -$67.85 Million | 103.56x | N/A |
Competitor Companies of OCGN by Market Capitalization
Companies near Ocugen Inc in the global market cap rankings as of November 4, 2026. Also see OCGN current and non-current assets for a full breakdown of the balance sheet.
Key companies related to Ocugen Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Ocugen Inc (2015–2026)
Market capitalization of Ocugen Inc from 2015 to today. Between 2015 and today, Ocugen Inc's market cap moved from $71.09 Billion to $ 252.27 Million, with a yearly change of -41.31%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $252.27 Million | -44.80% |
| 2025 | $457.00 Million | +67.70% |
| 2024 | $272.51 Million | +40.00% |
| 2023 | $194.65 Million | -55.77% |
| 2022 | $440.08 Million | -71.43% |
| 2021 | $1.54 Billion | +148.63% |
| 2020 | $619.49 Million | +251.92% |
| 2019 | $176.03 Million | -90.15% |
| 2018 | $1.79 Billion | -95.71% |
| 2017 | $41.64 Billion | +22.75% |
| 2016 | $33.92 Billion | -52.29% |
| 2015 | $71.09 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Ocugen Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $252.27 Million USD |
| MoneyControl | $252.27 Million USD |
| MarketWatch | $252.27 Million USD |
| marketcap.company | $252.27 Million USD |
| Reuters | $252.27 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Ocugen Inc
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase… Read more